Skip to content

Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)

Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04854447
Enrollment
30
Registered
2021-04-22
Start date
2019-11-15
Completion date
2021-11-25
Last updated
2021-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Myopia, Spectacles, Full-time correction, Part-time correction, Childhood

Brief summary

The purpose is to assess the effect of part-time compared to full-time spectacle use in juvenile myopia control.

Detailed description

A prospective, randomized, controlled clinical trial was designed for assessing the effect of single-vision spectacles on myopic progression. 30 myopic subjects, aged 6-16 years old, with a spherical equivalent refraction between -0.50D and -6.00D, were recruited. A random number table was used to allocate participants into either a) part-time use of single-vision spectacles, or b) full-time use of single-vision spectacles. Part-time use was for 4-6 hours a day, 7 days a week for a year. Clinical assessment included follow-up at 6 months and at 12 months upon allocation. The primary outcomes were a) change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction, and b) change in axial eye length (AL). The secondary outcomes were a) change in choroidal thickness (ChT), and b) assessment of the subjective tolerance.

Interventions

Spectacle correction for myopia treatment

Sponsors

State Scholarships Foundation
CollaboratorUNKNOWN
Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Age 4 to 16 years old at the time of enrollment. * Best-corrected visual acuity (BCVA) LogMAR 0.1 or better, in each eye. * Cycloplegic Autorefraction: Myopia, SER between -0.50D and -6.00D, in each eye. Astigmatism less than or equal to 1.50D, in each eye. Anisometropia less than or equal to 1.50D between the two eyes. * Absence of any ocular or systemic condition that could influence refractive development, other than myopia. * Eagerness to participate in this study and receive myopia treatment in a randomized fashion. Availability for at least 1-year follow-up. Subject parent's or guardian's understanding of the protocol and acceptance to participate, providing a signed consent on behalf of the subject.

Exclusion criteria

* Presence of strabismus. * Presence of amblyopia. * Prematurity (gestational age less than 37 weeks). * Presence of an ocular condition affecting refraction (ie. cataract, dislocated lens). * Presence of a systemic condition affecting refraction (ie. Down syndrome, Marfan syndrome). * Allergy to cyclopentolate. Severe ocular or systemic allergies.

Design outcomes

Primary

MeasureTime frame
Change in spherical equivalent refractive error (SER), measured using cycloplegic autorefraction.Baseline to 6-months, and baseline to 12-months.
Change in axial length (AL).Baseline to 6-months, and baseline to 12-months.

Secondary

MeasureTime frameDescription
Change in choroidal thickness (ChT).Baseline to 6-months, and baseline to 12-months.
Subjective tolerance, as assessed using a standardized questionnaire created for the purpose of this study.Baseline to 12-months.This questionnaire is formed by the researchers participating in this study and is aimed at providing a qualitative assessment of the subjective tolerance of included children wearing spectacles. It incorporates 6 questions and is not based on a scale.

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026